Insider Selling: Vera Therapeutics (NASDAQ:VERA) Insider Sells 2,187 Shares of Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) insider William Turner sold 2,187 shares of Vera Therapeutics stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $91,810.26. Following the transaction, the insider owned 45,313 shares in the company, valued at approximately $1,902,239.74. This represents a 4.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Vera Therapeutics Trading Down 1.6%

Shares of VERA traded down $0.69 during mid-day trading on Wednesday, reaching $41.68. The stock had a trading volume of 776,869 shares, compared to its average volume of 897,432. Vera Therapeutics, Inc. has a 52-week low of $18.53 and a 52-week high of $56.05. The firm has a market cap of $2.92 billion, a price-to-earnings ratio of -10.45 and a beta of 1.16. The business’s fifty day moving average is $46.63 and its 200 day moving average is $35.30. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on VERA shares. Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. JPMorgan Chase & Co. cut their target price on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a research note on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, January 21st. Bank of America increased their price target on Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Finally, The Goldman Sachs Group boosted their price objective on shares of Vera Therapeutics from $55.00 to $95.00 and gave the company a “buy” rating in a report on Friday, December 19th. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Vera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $77.18.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Vera Therapeutics by 7.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock valued at $753,000 after buying an additional 2,210 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Vera Therapeutics by 22.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock valued at $2,354,000 after acquiring an additional 17,907 shares during the period. Jane Street Group LLC boosted its holdings in Vera Therapeutics by 297.1% during the 1st quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock valued at $999,000 after acquiring an additional 62,678 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Vera Therapeutics in the 2nd quarter valued at about $237,000. Finally, Quinn Opportunity Partners LLC purchased a new stake in Vera Therapeutics during the second quarter worth about $448,000. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.